公开(公告)号：US20240382541A1

公开(公告)日：2024-11-21

申请号：US18665666

申请日：2024-05-16

Applicant: Boehringer Ingelheim International GmbH

Inventor： Martin DASS ,  Ludger Markus ICKENSTEIN ,  Thomas KRIEHUBER ,  Katharina REICHE

IPC: A61K35/766 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/42

Abstract: The present invention relates to viral formulations for administration to a subject.

公开(公告)号：US20240293352A1

公开(公告)日：2024-09-05

申请号：US18288617

申请日：2022-05-06

Applicant: Ottawa Hospital Research Institute ,  Colorado State University Research Foundation

Inventor： Jean-Simon Diallo ,  Debbie C. Crans ,  Rozanne Arulanandam

IPC: A61K31/28 ,  A61K33/42 ,  A61K35/766 ,  A61K35/768 ,  A61P35/00

CPC classification number: A61K31/28 ,  A61K33/42 ,  A61K35/766 ,  A61K35/768 ,  A61P35/00

Abstract: The present application relates to vanadium compounds. More specifically, the present application relates to pharmaceutical compositions comprising vanadium salts, use thereof and methods using the same. The present application also includes compositions comprising vanadium compounds and a therapeutic or prophylactic virus providing for increased virus infection, spread, titer, activity, cytotoxicity and/or immunotherapeutic activity.

公开(公告)号：US12076353B2

公开(公告)日：2024-09-03

申请号：US16763013

申请日：2018-11-23

Applicant: Ottawa Hospital Research Institute

Inventor： Jean-Simon Diallo ,  Mohammed Selman ,  Rozanne Arulanandam ,  Nicole Elise Forbes ,  Ramya Krishnan

IPC: C12N7/00 ,  A61K31/225 ,  A61K35/766 ,  A61P35/00 ,  C07C69/60 ,  A61K39/00

CPC classification number: A61K35/766 ,  A61K31/225 ,  A61P35/00 ,  C07C69/60 ,  C12N7/00 ,  A61K2039/585 ,  C12N2710/10332 ,  C12N2710/10351 ,  C12N2740/16134 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/20232 ,  C12N2760/20251

Abstract: Provided herein are fumaric and maleic acid-containing compounds, compositions comprising the same and methods for using such compounds to enhance production, growth, spread or titer of interferon-sensitive viruses in cells, particularly cancer and tumor cells. Also provided are methods of treating tumors or cancers in a subject by administering the compounds and compositions.

公开(公告)号：US20230285552A1

公开(公告)日：2023-09-14

申请号：US18307593

申请日：2023-04-26

Applicant: TURNSTONE LIMITED PARTNERSHIP

Inventor： Marie-Claude Bourgeois-Daigneault ,  John Bell

IPC: A61K39/39 ,  A61P37/04 ,  A61K35/761 ,  A61K35/766 ,  A61K35/768 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61P37/04 ,  A61K35/761 ,  A61K35/766 ,  A61K35/768 ,  A61K39/0011 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/545

Abstract: Herein is described oncolytic viruses for use as immunologic adjuvants. There is provided a method of adjuvanting an immune response to an antigenic protein in a mammalian subject by administering the oncolytic virus and at least one antigenic peptide, with the latter not encoded by the former. Without the requirement for the virus to encode the antigenic protein, therapies may be readily personalized or formulated. The virus may be attenuated or inactivated. Prime:boost therapies for tumours are also provided, in which the prime comprises at least one antigenic protein, the boost comprises a virus and at least one antigenic protein, the at least one antigenic protein of the prime and the at least one antigenic protein of the boost are based on the same at least one tumour associated antigen, and the at least one antigenic protein of the boost is not encoded by the virus of the boost.

公开(公告)号：US11654192B2

公开(公告)日：2023-05-23

申请号：US17020490

申请日：2020-09-14

Applicant: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.

Inventor： David F. Stojdl

IPC: C12N7/00 ,  A61K39/205 ,  A61K35/766 ,  C07K14/005 ,  A61K38/00 ,  A61K39/00

CPC classification number: A61K39/205 ,  A61K35/766 ,  C07K14/005 ,  C12N7/00 ,  A61K38/00 ,  A61K2039/572 ,  A61K2039/585 ,  C12N2760/00032 ,  C12N2760/20021 ,  C12N2760/20022 ,  C12N2760/20023 ,  C12N2760/20032 ,  C12N2760/20043

Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.

公开(公告)号：US20220296659A1

公开(公告)日：2022-09-22

申请号：US17611726

申请日：2019-12-06

Applicant: FANTASIA BIOPHARMA (ZHEJIANG) CO. LTD

Inventor： Frank Xiaofeng QIN

IPC: A61K35/766 ,  A61K31/192 ,  A61K45/06 ,  A61P35/00 ,  A61P11/00 ,  A61P35/04

Abstract: Provided are a pharmaceutical composition for treatment of a tumor or cancer, and an application thereof. The pharmaceutical composition comprises an oncolytic rhabdovirus and a small molecule CD38 inhibitor such as rhein that are administered via direct local injection or systemic administration or intratumoral delivery. The oncolytic rhabdovirus has the characteristic of recognizing tumor cells and would not cause damage to normal cells. Meanwhile, the small molecule CD38 inhibitor has the activity of specifically inhibiting T-cell receptor molecules. The combined use of the oncolytic rhabdovirus and the small molecule CD38 inhibitor has significant advantages in safety and efficacy.

公开(公告)号：US11446345B2

公开(公告)日：2022-09-20

申请号：US16474349

申请日：2018-01-03

Applicant: HANGZHOU CONVERD CO., LTD.

Inventor： Fang Hu ,  Lin Chen ,  Ronghua Zhao

IPC: A61K35/761 ,  A61P35/00 ,  A61K35/17 ,  A61K35/768 ,  A61K35/763 ,  A61K35/765 ,  A61K35/766 ,  A61K35/76

Abstract: The present disclosure provides therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic virus that selectively replicate in tumor cells and comprise NK cells.

公开(公告)号：US20220152168A1

公开(公告)日：2022-05-19

申请号：US17440639

申请日：2020-03-19

Applicant: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. ,  TURNSTONE BIOLOGICS INC.

Inventor： David Stojdl ,  Justyna KMIECIK ,  Michael F. BURGESS

IPC: A61K39/00 ,  A61K35/766 ,  A61K35/761 ,  A61K35/768

Abstract: The present disclosure relates to a sequential boost oncolytic viral immunotherapy and compositions for use in the same. More particularly, the disclosure relates to oncolytic viruses that significantly increase antigen-specific T cell-mediated immune responses when combined in a sequential heterologous boost treatment regimen.

公开(公告)号：US11110138B2

公开(公告)日：2021-09-07

申请号：US14654259

申请日：2013-12-20

Applicant: CELVERUM INC.

Inventor： David Conrad ,  Cory Batenchuk ,  Fabrice Leboeuf ,  John Cameron Bell

IPC: C12N7/04 ,  C12N7/06 ,  C07K14/00 ,  A61K35/766 ,  C12N7/00 ,  A61K45/06 ,  C07K14/005 ,  A61P35/02 ,  A01N63/00

Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.

公开(公告)号：US20210106632A1

公开(公告)日：2021-04-15

申请号：US16967074

申请日：2018-09-28

Applicant: TANDEM CO., LTD.

Inventor： Gi-Beom KIM ,  Yoo Soo YANG ,  In-San KIM ,  Gihoon NAM

IPC: A61K35/766 ,  A61P35/00 ,  C07K16/28 ,  A61K45/06

Abstract: The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162nd amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.